Spinocerebellar Ataxia with Axonal Neuropathy
Spinocerebellar Ataxia with Axonal Neuropathy
National Organization for Rare Disorders, Inc.
It is possible that the main title of the report Spinocerebellar Ataxia with Axonal Neuropathy is not the name you expected. Please check the synonyms listing to find the alternate name(s) and disorder subdivision(s) covered by this report.
Related Disorders List
Information on the following diseases can be found in the Related Disorders section of this report:
Spinocerebellar ataxia with axonal neuropathy (SCAN1) is a neurodegenerative disorder that is inherited in an autosomal recessive pattern. SCAN1 is characterized by late childhood-onset of a slowly progressive cerebellar ataxia, followed by areflexia and signs of peripheral neuropathy. Gaze nystagmus and cerebellar dysarthria usually develop after the onset of ataxic gait. As the disease advances, pain and touch sensation become impaired in the hands and legs; vibration sense disappears in hands and lower thigh. Individuals with advanced disease develop a steppage gait and pes cavus; and later become wheelchair dependent. Affected individuals have normal intellect and longevity.
SCAN1 is suspected in individuals with the following clinical features:
- Cerebellar ataxia and areflexia of late childhood (13 - 15 years)-onset followed by signs of peripheral neuropathy
- Slow progression
- Absence of oculomotor apraxia
- Absence of extra-neurological findings common in ataxia-telangiectasia (telangiectasias, immunodeficiency and cancer predisposition)
- Family history consistent with autosomal recessive inheritance
- MRI: Cerebellar atrophy especially of the vermis is present in all affected individuals
- Nerve conduction studies: Signs of axonal neuropathy
- Nerve biopsy: axonal loss
- Blood tests: Decreased serum concentration of albumin and increased serum concentration of cholesterol
SCAN1 is inherited as an autosomal recessive disorder. Recessive genetic disorders occur when an individual inherits two copies of an abnormal gene for the same trait, one from each parent. If an individual receives one normal gene and one gene for the disease, the person will be a carrier for the disease but usually will not show symptoms. The risk for two carrier parents to both pass the defective gene and have an affected child is 25% with each pregnancy. The risk to have a child who is a carrier like the parents is 50% with each pregnancy. The chance for a child to receive normal genes from both parents and be genetically normal for that particular trait is 25%. The risk is the same for males and females.
All individuals carry 4-5 abnormal genes. Parents who are close relatives (consanguineous) have a higher chance than unrelated parents to both carry the same abnormal gene, which increases the risk to have children with a recessive genetic disorder.
Biallelic mutations in the tyrosyl-DNA phosphodiesterase 1 (TDP1) gene are found in all individuals with SCAN1. The TDP1 gene encodes tyrosyl-DNA phosphodiesterase 1 (Tdp1) a DNA repair enzyme that is involved in correction of the DNA strand breaks in which the 3' end is blocked by stalled topoisomerase I or phosphoglycolate. The histidine at amino acid residue 493 (His493) is a key residue in the active site of Tdp1 and its mutation impairs enzymatic activity. In particular, the p.His493Arg mutation identified in SCAN1 reduces enzymatic activity 25-fold and results in accumulation of topoisomerase I DNA complexes. Also, the mutant Tdp1 forms a prolonged covalent intermediate with the DNA.
Consistent with these in vitro studies, lymphoblastoid cells from persons with SCAN1 are more sensitive to the camptothecins and radiation. Despite these findings, SCAN1 does not appear to arise solely from deficient functional Tdp1 because Tdp1-deficient mice have normal growth and survival under ideal growth conditions although they are highly sensitive to the camptothecins and bleomycin. This suggests that, at least in mice and yeast, redundant pathways exist for Tdp1 and that this redundancy is sufficient under ideal conditions.
Further analysis suggests that the pathology of SCAN1 can be partially attributed to the prolonged covalent intermediate state formed by the p.His493Arg Tdp1 because murine and yeast cells expressing the ortholog of the human p.His493Arg Tdp1 are more sensitive to DNA damaging agents than are Tdp1-deficientl cells. This latter observation would also provide an explanation for the rarity of SCAN1 because recurrence of the disease would require recurrence of the p.His493Arg mutation or a functionally equivalent mutation. The autosomal recessive inheritance of a neomorphic mutation is explained by the finding that the covalent intermediate formed by p.His493Arg Tdp1 is rapidly repaired by wild type Tdp1.
SCAN1 has been identified in a single Saudi Arabian family. It has not been identified in other ataxic individuals.
Partial symptomatic overlap with SCAN1 can be seen in several spinocerebellar ataxias including ataxia oculomotor apraxia 1 (AOA1), ataxia oculomotor apraxia 2 (AOA2), Friedreich ataxia (FRDA) and ataxia with vitamin E deficiency (AVED). AOA1 is characterized by early onset cerebellar ataxia, axonal neuropathy, oculomotor apraxia and chorea or dystonia. Serum concentration of albumin is decreased and total cholesterol is increased. The presence of oculomotor apraxia (80% of individuals with AOA1) differentiates AOA1 from SCAN1; however, this sign is not obvious in the early stages of the disease. AOA1 is caused by mutations of APTX.
AOA2 is characterized by early onset cerebellar ataxia, axonal neuropathy, oculomotor apraxia and chorea or dystonia. Serum concentration of alpha-fetoprotein (AFP) is increased. AOA2 is caused by mutations of SETX.
FRDA is characterized by slowly progressive ataxia of gait and limbs, extensor plantar responses, and is regularly accompanied by dysarthria and axonal (predominantly sensory) neuropathy. Areflexia and reduced vibration or position sense of the lower limbs are frequent signs. Progressive scoliosis and sensorineural hearing loss are common. The onset is usually before age 25 years (mean ranging between 11 and 20 years). FRDA can be distinguished from SCAN1 by the presence of extensor plantar responses, cardiomyopathy (detected by ECG or echocardiography), and/or the usual absence of cerebellar atrophy on CT/MRI. Molecular genetic testing of FRDA is helpful for diagnostic confirmation.
AVED is characterized by cerebellar ataxia, loss of proprioception and areflexia associated with markedly reduced plasma vitamin E (alpha-tocopherol) concentration. AVED can be treated by vitamin E supplementation. The diagnosis can be confirmed by identification of mutations in TTPA, the gene encoding the alpha-tocopherol transfer protein.
The diagnosis of SCAN1 is made on history and clinical signs as listed above. DNA testing for mutations in TDP1 is only available on a research basis.
Treatments are selected to address individual symptoms as they develop. Prostheses, walking aids, and wheelchairs are helpful for mobility depending on disabilities. Physical therapy may be helpful to maintain a more active lifestyle. Based on the proposed mechanism of disease, decreasing the predisposition of topoisomerase I to become trapped on the DNA might slow the progression of disease. Since oxidative damage of DNA is one factor that increases the amount of topoisomerase I stalled on the DNA, antioxidants may prove efficacious in affected individuals although this therapy has not been tried yet.
Information on current clinical trials is posted on the Internet at www.clinicaltrials.gov. All studies receiving U.S. government funding, and some supported by private industry, are posted on this government web site.
For information about clinical trials being conducted at the NIH Clinical Center in Bethesda, MD, contact the NIH Patient Recruitment Office:
Tollfree: (800) 411-1222
TTY: (866) 411-1010
For information about clinical trials sponsored by private sources, contact:
Anheim M, Monga B, Fleury M, Charles P, Barbot C, Salih M, et al. Ataxia with oculomotor apraxia type 2: clinical, biological and genotype/phenotype correlation study of a cohort of 90 patients. Brain. 2009;132(Pt 10):2688-98.
He, X., R. C. van Waardenburg, et al). Mutation of a Conserved Active Site Residue Converts Tyrosyl-DNA Phosphodiesterase I into a DNA Topoisomerase I-dependent Poison. J Mol Biol 2007;372(4): 1070-81.
El-Khamisy, S. F., E. Hartsuiker, et al. TDP1 facilitates repair of ionizing radiation-induced DNA single-strand breaks. DNA Repair (Amst) 2007;6(10): 1485-95.
Hirano, R., H. Interthal, et al. Spinocerebellar ataxia with axonal neuropathy: consequence of a Tdp1 recessive neomorphic mutation? EMBO J 2007;26(22):4732-43.
Katyal, S., S. F. el-Khamisy, et al. TDP1 facilitates chromosomal single-strand break repair in neurons and is neuroprotective in vivo. EMBO J 2007;26(22): 4720-31.
Miao, Z. H., K. Agama, et al. Hereditary ataxia SCAN1 cells are defective for the repair of transcription-dependent topoisomerase I cleavage complexes. DNA Repair (Amst) 2006;5(12): 1489-94.
Asaka, T., H. Yokoji, et al. Autosomal recessive ataxia with peripheral neuropathy and elevated AFP: novel mutations in SETX. Neurology 2006;66(10): 1580-1.
Bhidayasiri, R., S. L. Perlman, et al. Late-onset Friedreich ataxia: phenotypic analysis, magnetic resonance imaging findings, and review of the literature. Arch Neurol 2005;62(12): 1865-9.
El-Khamisy, S. F., G. M. Saifi, et al. Defective DNA single-strand break repair in spinocerebellar ataxia with axonal neuropathy-1. Nature 434(7029) 2005;108-13.
Interthal, H., H. J. Chen, et al. Human Tdp1 cleaves a broad spectrum of substrates, including phosphoamide linkages. J Biol Chem 2005;280(43): 36518-28.
Interthal, H., H. J. Chen, et al. SCAN1 mutant Tdp1 accumulates the enzyme-DNA intermediate and causes camptothecin hypersensitivity. Embo J 2005;24(12): 2224-33.
Moreira, M. C., S. Klur, et al. Senataxin, the ortholog of a yeast RNA helicase, is mutant in ataxia-ocular apraxia 2. Nat Genet 2004;36(3): 225-7.
Pommier, Y. Camptothecins and topoisomerase I: a foot in the door. Targeting the genome beyond topoisomerase I with camptothecins and novel anticancer drugs: importance of DNA replication, repair and cell cycle checkpoints. Curr Med Chem Anti-Canc Agents 2004;4(5): 429-34.
Plo, I., Z. Y. Liao, et al. Association of XRCC1 and tyrosyl DNA phosphodiesterase (Tdp1) for the repair of topoisomerase I-mediated DNA lesions. DNA Repair (Amst) 2003;2(10): 1087-100.
Davies, D. R., H. Interthal, et al. The crystal structure of human tyrosyl-DNA phosphodiesterase, Tdp1. Structure (Camb) 2002;10(2): 237-48.
Shimazaki, H., Y. Takiyama, et al.Early-onset ataxia with ocular motor apraxia and hypoalbuminemia: the aprataxin gene mutations. Neurology 2002;59(4): 590-5.
Takashima, H., C. F. Boerkoel, et al. Mutation of TDP1, encoding a topoisomerase I-dependent DNA damage repair enzyme, in spinocerebellar ataxia with axonal neuropathy. Nat Genet 2002; 32(2): 267-72.
Hirano, R, Salih, MAM, Takashima, H, and V Boerkoel, CF, (Posted October 22, 2007). Spinocerebellar Ataxia with Axonal Neuropathy, Autosomal Recessive. In: GeneReviews at GeneTests: Medical Genetics Information Resource (database online). Copyright, University of Washington, Seattle. 1997-2012. Available at: http://www.genetests.org. Accesssed on:January 16, 2012.
McKusick, VA, ed. Online Mendelian Inheritance in Man (OMIM); http://omim.org/entry/607250 Last updated: 2/2/06. Accessed on:January 16, 2012.
National Ataxia Foundation
2600 Fernbrook Lane Suite 119
Minneapolis, MN 55447
Canadian Association for Familial Ataxias - Claude St-Jean Foundation
3800 Radisson Street Office 110
Quebec, H1M 1X6
International Network of Ataxia Friends
Quebec, H7K 3R7
Genetic and Rare Diseases (GARD) Information Center
PO Box 8126
Gaithersburg, MD 20898-8126
For a Complete Report
This is an abstract of a report from the National Organization for Rare Disorders, Inc.® (NORD). Cigna members can access the complete report by logging into myCigna.com. For non-Cigna members, a copy of the complete report can be obtained for a small fee by visiting the NORD website. The complete report contains additional information including symptoms, causes, affected population, related disorders, standard and investigational treatments (if available), and references from medical literature. For a full-text version of this topic, see http://www.rarediseases.org/search/rdblist.html.
The information provided in this report is not intended for diagnostic purposes. It is provided for informational purposes only. NORD recommends that affected individuals seek the advice or counsel of their own personal physicians.
It is possible that the title of this topic is not the name you selected. Please check the Synonyms listing to find the alternate name(s) and Disorder Subdivision(s) covered by this report
This disease entry is based upon medical information available through the date at the end of the topic. Since NORD's resources are limited, it is not possible to keep every entry in the Rare Disease Database completely current and accurate. Please check with the agencies listed in the Resources section for the most current information about this disorder.
For additional information and assistance about rare disorders, please contact the National Organization for Rare Disorders at P.O. Box 1968, Danbury, CT 06813-1968; phone (203) 744-0100; web site www.rarediseases.org or email firstname.lastname@example.org
Last Updated: 1/24/2012
Copyright 2008, 2012 National Organization for Rare Disorders, Inc.
Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated.